IOVA — Iovance Biotherapeutics Share News
0.000.00%
Last trade - 00:00- $6.67bn
- $6.37bn
- $263.50m
Iovance Biotherapeutics falls on Q1 revenue miss
Iovance Biotherapeutics Q1 EPS misses analyst expectations, net loss widens
Brief: Iovance Announces Positive Results From The First Clinical Trial For Til Cell Therapy In Soft Tissue Sarcomas
Iovance Q4 revenue rises on Amtagvi demand
Iovance Biotherapeutics Q3 revenue up 13%, backs FY outlook
Brief: EMA's CHMP Recommended Five Extensions Of Indication For Medicines Bimervax, Dupixent, Keytruda
Brief: Iovance Biotherapeutics Enters Amended Sale Agreement With Jefferies
Brief: Iovance’s Amtagvi Receives Health Canada Approval for Advanced Melanoma
Iovance Biotherapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Iovance falls after Q2 revenue miss, wider loss
Explainer: What is behind the latest rally in meme stocks?
Replimune falls more than 70% as US FDA declines to approve skin cancer drug
Brief: Iovance Biotherapeutics Appoints Matthew Rosinack As Interim Principal Financial Officer
Brief: Iovance Biotherapeutics Says Confirming Resignation Of Chief Financial Officer Jean-Marc Bellemin, Effective July 10, 2025
Brief: Iovance Biotherapeutics Inc - Jean-Marc Bellemin To Resign As CFO
Brief: Iovance Announces Five-Year Results Of Amtagvi® (Lifileucel) In Patients With Advanced Melanoma At Asco Annual Meeting
Brief: Iovance Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
U.S. STOCKS ON THE MOVE-Netflix, Acadia Pharma, CoreWeave
UBS downgrades Iovance on sluggish uptake of skin cancer drug